Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Other Operating Expenses (2016 - 2025)

Lipocine (LPCN) has disclosed Other Operating Expenses for 13 consecutive years, with $607777.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses fell 28.09% year-over-year to $607777.0, compared with a TTM value of $3.0 million through Sep 2025, down 30.23%, and an annual FY2024 reading of $3.3 million, down 6.43% over the prior year.
  • Other Operating Expenses was $607777.0 for Q3 2025 at Lipocine, up from -$952571.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $3.5 million in Q4 2023 and bottomed at -$4.0 million in Q2 2021.
  • Average Other Operating Expenses over 5 years is $439274.3, with a median of $779376.0 recorded in 2021.
  • The sharpest move saw Other Operating Expenses tumbled 400000100.0% in 2021, then surged 84523400.0% in 2024.
  • Year by year, Other Operating Expenses stood at -$4.0 million in 2021, then skyrocketed by 106.25% to $250000.0 in 2022, then skyrocketed by 1290.1% to $3.5 million in 2023, then crashed by 30.75% to $2.4 million in 2024, then plummeted by 74.74% to $607777.0 in 2025.
  • Business Quant data shows Other Operating Expenses for LPCN at $607777.0 in Q3 2025, -$952571.0 in Q2 2025, and $952571.0 in Q1 2025.